The results from this study emphasize the importance of incorporating NETO2, HPN, AR, and KLK3 as part of a comprehensive model for prostate cancer prognosis, pointing towards their potential to improve clinical outcomes. This evidence concerns the gene NETO2 and prostate cancer.